title: Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
abstract: The serological response of the current 2009 H1N1 pandemic influenza monovalent vaccine in children exhibiting high baseline seropositive rate was evaluated though a community-based household study. Seroprotection rate of >90% and seroconversion rate of >50% were observed in children one month after receiving the pandemic vaccine. Among children with low baseline antibody titer, a significant lower seroconversion rate (55%) was observed in children who received seasonal trivalent inactivated vaccine (TIV) prior to pandemic vaccine, when compared with those receiving the pandemic vaccine only (86%). Persistence of antibody against the pandemic influenza virus was observed 6 months after vaccination in >80% of children presenting seroprotective antibody levels.
authors.affiliation: Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung-Hsing University, Taichung 401, Taiwan. dychao@nchu.edu.tw
authors.forename: Day-Yu
authors.initials: DY
authors.lastname: Chao
authors.forename: Kuang-Fu
authors.initials: KF
authors.lastname: Cheng
authors.forename: Ying-Hen
authors.initials: YH
authors.lastname: Hsieh
authors.forename: Tsai-Chung
authors.initials: TC
authors.lastname: Li
authors.forename: Trong-Neng
authors.initials: TN
authors.lastname: Wu
authors.forename: Chiu-Ying
authors.initials: CY
authors.lastname: Chen
authors.forename: Chen-An
authors.initials: CA
authors.lastname: Tsai
authors.forename: Jin-Hwa
authors.initials: JH
authors.lastname: Chen
authors.forename: Hsien-Tsai
authors.initials: HT
authors.lastname: Chiu
authors.forename: Jang-Jih
authors.initials: JJ
authors.lastname: Lu
authors.forename: Mei-Chi
authors.initials: MC
authors.lastname: Su
authors.forename: Yu-Hsin
authors.initials: YH
authors.lastname: Liao
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D058873:Pandemics / Q000517:prevention & control; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines